Detalhe da pesquisa
1.
Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead.
Clin Infect Dis
; 71(Suppl 2): S141-S150, 2020 07 29.
Artigo
Inglês
| MEDLINE | ID: mdl-32725225
2.
Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
N Engl J Med
; 374(12): 1155-66, 2016 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-27007959
3.
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
N Engl J Med
; 373(13): 1195-206, 2015 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-26214039
4.
Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
J Infect Dis
; 216(7): 834-841, 2017 10 17.
Artigo
Inglês
| MEDLINE | ID: mdl-28968794
5.
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Lancet
; 384(9951): 1358-65, 2014 Oct 11.
Artigo
Inglês
| MEDLINE | ID: mdl-25018116
6.
Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Lancet Glob Health
; 12(5): e826-e837, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38614631
7.
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
Lancet
; 380(9853): 1559-67, 2012 Nov 03.
Artigo
Inglês
| MEDLINE | ID: mdl-22975340
8.
A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
Hum Vaccin Immunother
; 19(1): 2203634, 2023 12 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37128723
9.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
medRxiv
; 2023 Jan 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36523415
10.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Lancet Respir Med
; 11(11): 975-990, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37716365
11.
Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal.
Hum Vaccin Immunother
; 18(5): 2051413, 2022 11 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35353657
12.
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Lancet Reg Health West Pac
; 24: 100484, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35664443
13.
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
NPJ Vaccines
; 7(1): 12, 2022 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-35087084
14.
Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
Vaccine
; 40(40): 5828-5834, 2022 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36064672
15.
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Lancet Infect Dis
; 22(4): 529-540, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34942090
16.
Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
Vaccine
; 39(22): 3028-3036, 2021 05 21.
Artigo
Inglês
| MEDLINE | ID: mdl-33583673
17.
Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal.
Hum Vaccin Immunother
; 17(7): 2149-2157, 2021 07 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33524278
18.
Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
Expert Rev Vaccines
; 19(8): 691-698, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32838605
19.
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Vaccine
; 38(28): 4476-4483, 2020 06 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31585725
20.
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
EClinicalMedicine
; 27: 100540, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-33150320